Phase I clinical trial to compare the safety and immunogenicity of CH505TF gp120 produced from stably transfected cells to CH505TF gp120 produced from transiently transfected cells in healthy, HIV-1 uninfected adult participants. The goal of this study is to compare two different methods of HIV-1 vaccine production. HIV-1-uninfected people will be immunized with an HIV-1 vaccine candidate Env protein (CH505TF gp120) manufactured with either stably transfected or transiently transfected cells. If we can show that the two methods give similar vaccine responses, we can pursue manufacture of future vaccine candidates by transient transfection, and this may help to accelerate the development process of future HIV-1 vaccines.

Check here for more details!